BioPharmSignal logoBioPharmSignal

Biotech News

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

Kiniksa (KNSA)KiniksaConference / presentation

LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21 st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.

Related news

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

XFORX4 Pharmaceuticals2026-09-09 11:00 EST

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

ELDNEledon Pharmaceuticals, Inc.2026-09-09 11:00 EST

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

ACRSAclaris Therapeutics2026-09-03 12:00 EST

Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

KNSAKiniksa2026-07-23 20:01 EST

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

INMBINmune Bio2026-09-09 12:00 EST

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

CLDXCelldex Therapeutics2026-09-08 20:01 EST

Celldex to Present at Upcoming Investor Conference

ANABAnaptysBio, Inc.2026-09-01 20:15 EST

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

View all latest news

Kiniksa

IL-1 Cardiovascular Franchise Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling. ARCALYST ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine...

Recent company news

KNSAKiniksa2026-09-04 20:01 EST

Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference

KNSAKiniksa2026-08-07 20:01 EST

Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference

KNSAKiniksa2026-07-28 11:30 EST

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

KNSAKiniksa2026-07-23 20:01 EST

Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026

KNSAKiniksa2026-05-29 20:01 EST

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

Stock data

Close
79.33 USD
Market cap
3.61B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States